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Abstract: Gastrointestinal stromal tumour (GIST) is a disease of older adults and is dominated by
KIT/PDGFR mutations. In children, GIST is rare, predominantly occurs in girls, has a stomach location
and generally lacks KIT/PDGFR mutations. For young adults (YA), aged 18 to 40 years, the typical
phenotypic and genotypic patterns are unknown. We therefore aimed to describe the clinical,
pathological and molecular characteristics of GIST in in YA. YA GIST patients registered in the Dutch
GIST Registry (DGR) were included, and data were compared to those of older adults (OA). From
1010 patients in the DGR, 52 patients were YA (54% male). Main tumour locations were stomach (46%)
and small intestine (46%). GIST genetic profiles were mutations in KIT (69%), PDGFRA (6%), SDH
deficient (8%), NF1 associated (4%), ETV6-NTRK3 gene fusion (2%) or wildtype (10%). Statistically
significant differences were found between the OA and YA patients (localisation, syndromic and
mutational status). YA presented more often than OA in an emergency setting (18% vs. 9%). The
overall five-year survival rate was 85%. In conclusion, YA GISTs are not similar to typical adult
GISTs and also differ from paediatric GISTs, as described in the literature. In this series, we found a
relatively high percentage of small intestine GIST, emergency presentation, 25% non-KIT/PDGFRA
mutations and a relatively good survival.
Keywords: GIST; young-adult patients; mutations; treatment; outcome
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1. Introduction
Gastrointestinal stromal tumours (GISTs) are found throughout the gastrointestinal tract and arise
from interstitial cells of Cajal [1]. Their estimated incidence is 10–15 per million [2]. GIST patients have
a median age at diagnosis of 65 years, and less than 10% are diagnosed before the age of 40 [3–5].
The distinct presentation of paediatric GISTs is well described in the literature. While GISTs in
adults arise in the stomach (40–60%) or in the small intestine (25–40%), in children, the stomach (90%)
is the predominant site of origin, and multifocal GISTs are common [6,7]. Furthermore, in children,
GISTs have a female predilection [8] and are more often associated with genetic syndromes, such as
the Carney–Stratakis syndrome, Carney’s triad syndrome and Neurofibromatosis type 1 (NF1) [9–11].
Regarding mutational status, adult GISTs are commonly driven by activating mutations in either
the KIT proto-oncogene (75%) or the PDGFRA (platelet-derived growth factor receptor A) oncogene
(15%) [1,12,13], and 10% were formerly named wildtype (WT) for KIT and PDGFRA [14]. However,
genetic research has unveiled other sporadic genetic alterations leading to GISTs, including RAS pathway
gene mutations and mutations in the four succinate dehydrogenase (SDH) subunits [15–17]. Therefore,
the description WT GIST is disappearing, and it is now common practice for oncologists to describe
which genetic alterations patients have been tested for [18]. In contrast to the molecular characteristics
of adults with GIST, children are KIT and PDGFRA WT in the vast majority (85–90%) [7,19–22]. Finally,
metastases in adults are mostly located intra-abdominally [1,23], whereas, in children, lymph node
and lung metastases are more common [24].
In addition to the classical paediatric and adult GIST presentation as defined above, a rare
‘paediatric-type’ presentation of GIST in (young) adults has been described in the literature, as well.
Despite their adult age, these ‘paediatric-type’ GISTs are KIT/PDGFR WT and present with gastric
lesions with multinodular or plexiform growth pattern and epithelioid or mixed cell histology. The
‘paediatric-type’ GIST predominantly affects women, often metastasizes to the lymph nodes and has a
relatively indolent course of disease [25].
The young adult (YA) population has gained recognition in oncological research as a group with
not only specific psychosocial needs but also distinct biological features [26–28]. The literature on both
clinical and biological GIST characteristics in YA is scarce. This retrospective cohort study aims to
describe the clinical, pathological and molecular characteristics of GIST in YA patients.
2. Results
2.1. Patient Characteristics
From 1010 patients registered in the Dutch GIST Registry (DGR) in March 2019, 52 YA patients
(aged 18 to 40 years, 5%) were identified (Table 1). A small majority was male (54%), and the median age
at diagnosis was 35 years (range 18–40). The main primary tumour locations were stomach (46%) and
small intestine (ileum/jejunum/duodenum, 46%); median tumour size at diagnosis was 60 mm; and 87%
had local disease at diagnosis. Two patients had multifocal GIST: one patient with a germline mutation
(small bowel) and one patient without a known familial syndrome (stomach). Four YA patients had a
known genetic predisposition for GIST, and three patients had a second malignancy (one patient had
melanoma, one patient malignant peripheral neural sheath tumour (MPNST) and one patient also had
breast and thyroid cancer). Most of the metastases that occurred were intra-abdominal/peritoneal or
in the liver, with only one case of lymph node metastases. The most common symptom was active
gastrointestinal bleeding (22%). In eight asymptomatic patients, the GIST was a coincidental finding.
According to the Miettinen risk classification, 21 patients had at baseline a high-risk tumour (41%).
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Table 1. Clinical and tumour characteristics of total young-adult (YA) age group.
Characteristic Total (%)
No. of YA Patients 52 (100)
Median age at Diagnosis (Range) 35 years (18–40)
Gender
Male 28 (53.8)
Female 24 (46.2)
Median Baseline Tumour Size in mm (Range) 60 (6–370)
Location
Gastric 24 (46.2)
Small intestine 24 (46.2)
Rectum 3 (5.8)
Oesophageal–cardiac junction 1 (1.9)
Syndromic Presentation
No
Yes
39 (90.7)
4 (9.3)
Neurofibromatosis 1 2
Carney triad 1
KIT exon 11 germline mutation 1
Unknown 9
Symptoms at Diagnosis *
Active gastrointestinal bleeding 11 (22.4)
Abdominal pain 9 (18.4)
Weight loss 9 (18.4)
Mass related symptoms (e.g., reflux, palpable mass, distended abdomen) 7 (14.3)
Anaemia related symptoms 6 (12.2)
Acute abdomen 6 (12.2)
Nausea/vomiting 4 (8.2)
Change in bowel habits 3 (6.1)
Analysis vitamin B12 deficiency 1 (2.0)
None (GIST coincidental finding) 8 (16.3)
Unknown 3
Second Malignancies
No 49 (94.2)
Yes 3 (5.8)
Tumour Status at Diagnosis
Local disease 45 (86.5)
Metastasized 7 (13.5)
Risk Classification
None
Low
2 (3.9)
19 (37.3)
Moderate 9 (17.6)
High
Unknown
21 (41.2)
1
* Multiple symptoms at diagnosis possible. GIST = Gastrointestinal stromal tumour.
2.2. Pathology
The histology of the primary tumours was predominantly spindle cell (76%), and the baseline
mitotic rate was low in 69% (Table 2). GIST genetic profiles were reported asKIT mutation 69%, PDGFRA
mutation 6%, SDH deficient 8%, NF1 associated 4%, ETV6-NTRK3 (translocation-Ets-leukaemia virus
and neurotrophic tyrosine kinase, only tested in one of the WT patients) gene fusion 2%, quadruple
WT 6%, triple WT 2% and KIT/PDGFRA WT 2%. The WT tumours were located in the stomach (4/5)
and in the small intestine (1/5). Altogether, 25% of the patients had a non-KIT/PDGFR mutation. One
patient had a double primary mutation: KIT exon 11 and KIT exon 9.
2.3. Treatment
Patients in Dutch GIST centres are generally treated according to standard guidelines. Of all YA
patients in this cohort, 14 received neoadjuvant treatment (30%). Of the 45 patients with localized
disease, three did not undergo surgery, as a result of progressive disease on neoadjuvant therapy
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(two) or comorbidities (one). Two patients received surgery of their primary tumour in the metastatic,
emergency setting. In total, 44 patients underwent surgery of the primary tumour (85%) (Figure 1).
In eight patients, emergency surgery was performed due to perforation or active bleeding (six small
intestine; two gastric). The resection margins were microscopically free from tumour in 93%, and
five patients (11%) had complications, with none requiring further surgery. Of the 44 surgically
treated patients, seven patients received neoadjuvant and adjuvant treatment and 12 received adjuvant
treatment only.
Table 2. Pathology and tumour genetic results of young-adult patients.
Characteristic No. (%)
Histology
Spindle cell 37 (75.5)
Epithelioid 3 (6.1)
Mixed type 9 (18.4)
Not reported 3
Baseline Mitotic Rate
Low (≤ 5/5 mm2) 35 (68.6)
High (> 5/5 mm2) 16 (31.4)
Unknown 1
Mutation Status
KIT 34 (69.4)
Exon 11 * 32
Exon 9 3
PDGFRA 3 (6.1)
D842V 2
Non-D842V 1
SDH deficiency 4 (8.2)
NF1 associated 2 (4.1)
ETV6-NTRK3 gene fusion 1 (2.0)
KIT/PDGFRA WT (BRAF and/or SDH not performed) 1 (2.0)
Triple WT (SDH not performed) 1 (2.0)
Quadruple WT 3 (6.1)
No mutational analysis performed 3
* One patient had both an exon 11 and exon 9 mutation in the primary tumour. NF1 = neurofibromatosis type 1;
WT = wildtype.
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Figure 1. Study flowchart. * various reasons, such as metastatic disease, significant comorbidity,
irresectable tumours or patients’ preference. DGR = Dutch GIST Registry; YA = young adult;
OA = older adult.
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2.4. Outcome
With a median follow-up time of 52 months (95% Confidence Interval (CI): 31.5–72.5), the median
overall survival (OS) for the YA patients was 8.9 years (95% CI: 7.4–10.4), with an estimated five-year
survival rate of 85% (95% CI: 71.6–97.5). Of the 44 patients with resection of the primary tumour,
13 (30%) developed recurrence: two local, eight distant and three both local and distant recurrences.
The median follow-up time in older adults (OA) was 37 months (95% CI: 33.0–41.0). The median
OS time was not reached, but the estimated five-year survival rate was 76% (95% CI: 72.2–79.7). There
was no significant difference in OS between the YA and OA patients (p = 0.10) (Figure 2).
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2.5. Impact of GIST on Life
In 56% of all patients, the psychosocial impact of their disease on life was both discussed by the
oncologist and noted in the electronic patient record (EPR). This was 15% for the possible influence
of the disease or treatment on fertility. The (in)ability to work/study was discussed and noted in 12
(46%) of the 26 patients receiving (neo) adjuvant therapy; seven patients (58%) had no limitations,
four reported to be working/studying less than before diagnosis; and one could no longer continue
work/study. For the 18 YA patients treated in the palliative setting, (in)ability to work/study was
discussed and noted in eight (44%), of which one (13%) reported no limitations; five were (63%)
studying/working less than before; and two (25%) stopped working/studying altogether. Eleven
patients were referred to a clinical geneticist.
2.6. Comparison of Age Groups
2.6.1. Comparison within the YA Cohort
Group 1 (age 18–29 years, median 26) consisted of 15 patients, and group 2 (30–40 years, median
38) of 37 patients. No significant differences in clinical and tumour characteristics were found between
the two YA age subgroups (Table 3). Furthermore, no differences were found in OS (p = 0.81) nor in
RFS (p = 0.75). Concerning the mutation distribution among the YA cohort, no clear turning point was
found where more wildtypes in younger patients (as in paediatric population) shifted to more KIT
mutated patients in older patients (as in adult population) (Figure 3).
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Table 3. Clinical and tumour characteristics within the young-adult age group.
Characteristic 18–29 Years(n = 15)
30–40 Years
(n = 37) p-Value
Median Age at Diagnosis (Range) 26 (18–29) 38 (30–40)
Gender 0.07
Male 5 (33.3) 23 (62.2)
Female 10 (66.6) 14 (37.8)
Median Baseline Tumour Size in mm
(Range) 45 (14–170) 60 (6–370) 0.23
Primary Site Grouped 0.48
Gastric 5 (33.3) 19 (51.4)
Small intestine 9 (60.0) 15 (40.5)
Other 1 (6.7) 3 (8.1)
Histology 0.74
Spindle cell 12 (80.0) 24 (73.5)
Epithelioid 0 (0.0) 3 (8.8)
Mixed type 3 (20.0) 6 (17.6)
Unknown 0 3
Tumour Status at Diagnosis 1.00
Local disease 13 (87.7) 32 (86.5)
Metastasized 2 (13.3) 5 (13.5)
Risk Category 0.53
Low/moderate 7 (46.7) 23 (62.2)
High 7 (53.3) 14 (37.8)
Unknown 1 0
Mutation Status 0.72
KIT 10 (66.7) 24 (70.6)
PDGFRA 0 (0.0) 3 (8.8)
SDH deficient 2 (13.3) 2 (5.9)
NF1 associated 1 (6.7) 1 (2.9)
ETV6-NTRK3 gene fusion 0 (0.0) 1 (2.9)
WT (min. KIT and PDGFRA)
Unknown
2 (13.3)
0
3 (8.8)
3
Baseline Mitotic Rate 0.32
Low (≤ 5/5 mm2) 8 (57.1) 27 (73.0)
High (> 5/5 mm2)
Unknown
6 (42.9)
1
10 (27.0)
0
Surgery 0.41
Yes
No
14 (93.3)
1 (6.7)
30 (81.1)
7 (18.9)
Patients who Received Surgery 14 (93.3) 30 (81.1) 0.41
Resection Margin 0.26
Negative (R0) 12 (85.7) 27 (96.4)
Positive (R1/R2) 2 (14.3) 1 (3.6)
Unknown 0 2
Tumour Rupture 1.00
No 11 (84.6) 24 (80.0)
Yes 2 (15.4) 5 (20.0)
Unknown 1 1
NF1 = neurofibromatosis type 1; WT = wildtype.
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2.6.2. Comparison between the YA and OA Patients
The OA age group consisted of 958 patients (Table 4). Tumours were significantly more often
localized in the small intestine in the YA age group, as compared to the OA age group (46% vs. 28%,
p = 0.03). YA patients had a syndromic presentation more often than the OA age group (p = 0.047).
Furthermore, YA patients significantly more often had non-KIT/PDGFRA positive tumours than patients
in the OA group (25% vs. 11%, respectively; p = 0.008). Concerning treatment, YA patients tended to
have surgery in an emergency setting more often than OA patients (18% vs. 9%, p = 0.06) (Figure 1). YA
patients did not present more often with metastatic disease compared to OA (13.5% vs. 24.6%, p = 0.09).
Furthermore, no significant differences were found between the two groups in gender, primary tumour
size, risk classification, histology, baseline mitotic rate or the number of patients receiving surgery.
Table 4. Clinical and tumour characteristics in the young adult (YA) and older adult (OA) age groups.
Characteristic Total (%)n = 1010
YA (%)
n = 52
OA (%)
n = 958 p-Value
Median Age at Diagnosis (range) 64 (18–95) 35 (18–40) 65 (41–95)
Gender 0.89
Male 533 (52.8) 28 (53.8) 505 (52.7)
Female 477 (47.2) 24 (46.2) 453 (47.3)
Median Baseline Tumour Size in mm
(Range) 72 (1–1000) 60 (6–370) 73 (1–1000) 0.09
Primary Site Grouped 0.03 *
Gastric
Small intestine
Other
604 (60.7)
290 (29.1)
101 (10.2)
24 (46.2)
24 (46.2)
4 (7.7)
580 (61.5)
266 (28.2)
91 (10.3)
Syndromic Presentation 0.047 *
No 799 (96.7) 39 (90.7) 760 (97.1)
Yes 27 (3.3) 4 (9.3) 23 (2.9)
Unknown 184 9 175
Tumour Status at Diagnosis 0.09
Local disease 767 (76.0) 45 (86.5) 722 (75.4)
Metastasized 242 (24.0) 7 (13.5) 235 (24.6)
Unknown 1 0 1
Histology 0.26
Spindle cell 739 (78.3) 37 (75.5) 702 (78.4)
Epithelioid 94 (10.0) 3 (6.1) 91 (10.2)
Mixed type 111 (11.8) 9 (18.4) 102 (11.4)
Unknown 66 3 63
Baseline Mitotic Rate 0.76
Low (≤5/5 mm2) 491 (66.4) 35 (68.6) 462 (66.2)
High (>5/5 mm2) 252 (33.6) 16 (31.4) 236 (33.8)
Unknown 261 1 260
Mutation Status 0.001 *
KIT 630 (75.9) 34 (69.4) 596 (76.3)
PDGFRA 106 (12.8) 3 (6.1) 103 (13.2)
BRAF 1 (0.1) 0 1 (0.1)
SDH deficiency 13 (1.6) 4 (8.2) 9 (1.2)
NF1 associated 16 (1.9) 2 (4.1) 14 (1.8)
ETV6-NTRK3 gene fusion 1 (0.1) 1 (2.0) 0
Wildtype (at least KIT and PDGFRA) 63 (7.6) 5 (10.2) 58 (7.4)
Unknown 180 3 177
KIT/PDGFRA vs. non-KIT/PDGFRA 0.008 *
KIT/PDGFRA 736 (88.7) 37 (75.5) 699 (89.5)
Non-KIT/PDGFRA 94 (11.3) 12 (24.5) 82 (10.5)
Patients who Received Surgery 793 (78.5) 44 (84.6) 749 (78.2) 0.30
Surgery Setting 0.06
Planned operation 712 (90.7) 36 (81.8) 676 (91.2)
Emergency setting 73 (9.3) 8 (18.2) 65 (8.8)
Unknown 8 0 8
* p-value < 0.05 was considered significant; NF1 = neurofibromatosis type 1.
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3. Discussion
This study shows that GIST at YA age is rare, representing only 5% of a large database. Paediatric
GISTs have a female predilection and are rarely KIT/PDGFRA mutated [6]. With an almost equal gender
distribution and increased presence of KIT or PDGFRA mutations, YA GISTs differ from paediatric
GIST. However, YA GISTs are also not fully similar to the typical adult GISTs either, as they have a
lower percentage of KIT and PDGFRA mutations (76% vs. 90%) and are more frequently located in the
small intestine (46% vs. 28%). Within the YA age group, we could not demonstrate a clear turning
point in age at which the mutational status shifted from WT to KIT/PDGFRA mutation, but that may be
due to the still relatively small number of YA patients.
Comparison of the data from this study with age-related GIST data in the existing literature is
challenging. This is due to the scarcity of GIST data in the YA population, the divergent composition
of age-groups studied and the incomplete reporting on mutational status. Three studies reported
on individual patients, and we used these data to construct a YA (18–29) and a paediatric age group
(<18) [19,22,29]. Fero et al. studied a large AYA population (13–39) and an OA population (≥40);
however, they did not report on mutational status [30] (Supplementary Table S1). The almost-equal
gender distribution in the YA and OA cohort of this study is in accordance with the large AYA and
OA population studied by Fero et al. [30]. Small intestine localisation seems to be less prevalent in
the OA population compared with the YA population of this study, which is in line with the previous
literature. Furthermore, this study confirmed that YA patients do not significantly more often present
with metastatic disease compared to the OA population.
Concerning the mutational status, which was only scarcely reported before, our results were
similar to the very small population (n = 30) of the combined studies of Prakash and Kang [19,29]. The
amount of KIT and PDGFRA mutations does not seem to be as low as in paediatric patients, but also
not as high as in OA patients. Since we found no clear turning point, there seems to be more evidence
for a gliding scale, where an increase in age also increases the probability of a KIT/PDGFRA mutated
GIST [31]. In two recent studies conducted in wildtype GIST patients, the reported median ages were
21 and 23 years, which supports the theory that most WT GISTs occur at a younger age [32,33].
In our cohort, YA GIST patients tended to undergo surgery more often in an emergency setting
compared to OA. The relatively high percentage of small-intestine localisations might account for
this [34]. Another possible explanation would be that the rarity of GIST at the YA age leads to a
delay in (correct) diagnosis. Delay of diagnosis in sarcomas, especially at this age, remains a problem,
and efforts to educate doctors and patients should be continued [35].
In over half of these young adults, the impact of the disease on life was not documented in their
file and therefore possibly not discussed. For these YA patients who are diagnosed with cancer in the
prime time of their lives, it is essential to take psychosocial factors (e.g., relationships, fertility, sexuality,
financial toxicity and workability) into account. With a five-year survival of 85%, these survivorship
issues are not trivial.
The five-year OS reported in this study is in line with the 82.4% five-year OS reported by Fero et al.
in a large cohort of AYA patients aged 13–39, with GIST [30]. A study conducted in elderly (≥75 years)
GIST patients reported a median OS of just 34 months [31]. The five-year survival rate of YA in our
cohort seemed superior to the survival rate of OA (85% vs. 76%), but this was not significant. Notably,
there was a difference in median follow-up, and the influence of other age-related factors, such as
comorbidities, was not corrected for and could also explain (a part of) the difference in survival rate.
As a side note, several Dutch databases with paediatric cancer patients were searched for GIST,
and over the same time period, only one paediatric patient was diagnosed. This illustrates how
extremely rare paediatric GIST is.
For future research, it would be interesting to compare separate molecular subgroups between the
YA and OA patients, in order to find out if the differences between the age groups persist. However,
since GIST in YA patients is rare, and molecular subgroups are therefore extremely small, this research
question can only be answered in an international setting, with an adequate sample size. Although the
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data was obtained from the DGR, a database containing information on GIST patients diagnosed for 10
years, the rarity of YA GIST makes that the numbers are still relatively small. Moreover, when the DGR
was established, it was not common practice to test for NTRK fusion genes and BCOR gene mutations.
Despite these limitations, this study on YA GIST is the largest series of a national population, including
mutational status. Given its therapeutic implications, it is recommended to test from now on the
quadruple WT GISTs for NTRK (neurotrophic tyrosine kinase) fusion genes as part of standard care.
4. Materials and Methods
4.1. Patient Selection and Variables
All patients who were 18 to 40 years old at diagnosis, who were diagnosed with GIST between
January 2009 and January 2019 and who were registered in the Dutch GIST Registry (DGR) were
included. The DGR is a prospectively maintained database, including patients ≥18 years with
GIST treated in one of the five Dutch GIST centres (LUMC Leiden, Erasmus MC Rotterdam, UMC
Groningen, Radboud UMC Nijmegen and the Netherlands Cancer Institute Amsterdam). Patient
(age, gender, symptoms at diagnosis, presence of second malignancies and syndromic presentation),
tumour (location, size, status at diagnosis (e.g., localized disease or metastatic disease), pathology
(histology, mitotic rate and mutation status), treatment (surgery yes/no, surgery setting (e.g., emergency
setting, planned operation for GIST and planned other surgery), (neo)adjuvant therapy yes/no) and
follow-up data were obtained from the database. Furthermore, clinical, treatment and outcome data
of all older adults (OA, >40 years old) were collected from the DGR, to compare data between OA
and YA. Within the comparison of tumour location, locations with less than 100 patients in the OA
group were classified as ‘other’. The DGR was approved by the local independent ethics committee
(PTC14.0057). We adhered to the STROBE guidelines for cohort studies.
4.2. Pathology
GIST diagnosis was confirmed by positive immunohistochemistry (IHC) for CD117 and/or DOG1.
Histology was described as spindle cell, epithelioid cell or mixed cell type. The required total
count of mitoses is per 5 mm2 on the glass slide section. With the use of older model microscopes,
50 HPF was used which we considered semi-equivalent to 5 mm2. Low mitotic rate was defined as
≤5 mitoses/5 mm2 and high as > 5 mitoses/5 mm2. GIST specific mutations tested by Next Generation
Sequencing (NGS) were KIT, PDGFRA and BRAF. Patients without KIT/PDGFRA/BRAF mutations
and where no SDH analysis was performed were considered triple wildtype (WT). Patients without
KIT/PDGFRA/BRAF mutations and SDHB deficiency (considered deficient in the absence of SDHB
protein expression on IHC [36]) were considered quadruple WT. Based on size, tumour site and mitotic
activity, patients were subdivided into risk classification groups according to Miettinen’s criteria [37].
4.3. Quality of Life
In this YA cohort, it was explored how often the psychosocial impact on life (e.g., depression,
body image and relationships), influence on fertility and (in)ability to work was documented explicitly
in the EPR by the medical oncologist. Whether or not this had been discussed with a patient was
purely based on documentation in the EPR. Data on referral to a clinical geneticist were also collected.
4.4. Statistical Analyses and Outcome
Statistical analyses were performed by using SPSS Statistics (IBM Corporation, version 25.0,
Armonk, NY, USA). Survival estimates were obtained, using the Kaplan–Meier method, and compared
by the log-rank test. Overall survival (OS) was calculated from the date of diagnosis to the date of
death or last follow-up. Follow-up time was estimated with the reversed Kaplan–Meier method.
Two subgroups within the YA group were compared: 18–29 years vs. 30–40 years. The comparative
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analyses were done by using Fisher’s exact test for categorical variables or Mann–Whitney U test for
numeric variables.
5. Conclusions
YA with GIST are rare and differ from OA with GIST, but they also differ from paediatric GIST,
as described in the literature. In this series, YA patients had a relatively high percentage of small
intestine localisation and relatively often presented in the acute setting. Absence of both KIT and
PDGFRA mutations was seen in 25% of YA patients. A relatively favourable five-year OS of 85%
was observed.
Supplementary Materials: The following is available online at http://www.mdpi.com/2072-6694/12/3/730/s1.
Table S1: Adolescents and young adults (AYA) age-related GIST data in the existing literature.
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